SI-BONE received FDA clearance to market iFuse-TORQ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures (those related to low-energy traumatic events) and pelvic insufficiency fractures.
Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where:
120,000 sacral fragility or insufficiency fractures occur annually in the U.S.
78% of patients are treated with bed rest, leading to 14- to 45-day hospital stays
27% 1-year mortality results from bed rest-associated complications
“Since its launch in 2021, iFuse-TORQ has been used to treat many patients suffering from a pelvic fracture or sacroiliac joint dysfunction,” said Laura Francis, CEO of SI-BONE. “This pelvic fracture fixation indication expansion comes on the coattails of the iFuse Bedrock Granite launch and expands SI-BONE’s position as the market leader in the sacropelvic space.”
SI-BONE received FDA clearance to market iFuse-TORQ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures (those related to low-energy traumatic events) and pelvic insufficiency fractures.
Sacral fragility and insufficiency fractures are...
SI-BONE received FDA clearance to market iFuse-TORQ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures (those related to low-energy traumatic events) and pelvic insufficiency fractures.
Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where:
120,000 sacral fragility or insufficiency fractures occur annually in the U.S.
78% of patients are treated with bed rest, leading to 14- to 45-day hospital stays
27% 1-year mortality results from bed rest-associated complications
“Since its launch in 2021, iFuse-TORQ has been used to treat many patients suffering from a pelvic fracture or sacroiliac joint dysfunction,” said Laura Francis, CEO of SI-BONE. “This pelvic fracture fixation indication expansion comes on the coattails of the iFuse Bedrock Granite launch and expands SI-BONE’s position as the market leader in the sacropelvic space.”
Copy to clipboard 
